Cadila Healthcare
-
Franchise India Bureau Sep 18 2018 - 1 min readAhmedabad-based Cadila Healthcare is planning to launch 50 products in the US during the current fiscal year. The company has at least ten para IV filings for the US. If a company files an abbreviated new drug application (ANDA) containing a paragraph IV certification with the US Food and Drug Administration (USFDA), then its product ...
-
Franchise India Bureau Mar 26 2018 - 1 min readDrug firm Zydus Cadila has received the final nod from US health regulator to market Metoprolol Succinate extended-release tablets, used for treatment of various cardiac conditions, in the American market. The product will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad, Zydus Cadila said in a statement.
-
Franchise India Bureau Mar 01 2018 - 1 min readDrug firm Zydus Cadila has confirmed to have received the final approval from US health regulator FDA to market Dexmedetomidine Hydrochloride injection used for sedation of patients under intensive care. Zydus Cadila in a regulatory filing said the approval from USFDA is to market Dexmedetomidine Hydrochloride injection 200 mcg (base)/ 2 ...
-
Franchise India Bureau Sep 29 2017 - 1 min readDrug firm Zydus Cadila has said the US health regulator has approved the group's plans to initiate phase II clinical trials of Saroglitazar Magnesium in patients suffering from a certain liver disease.In a statement, Zydus Cadila, said, "The United States Food and Drug Administration (USFDA) has approved the group's plans to initiate a phase II ...